Weight Loss with GLP-1s in Everyday Care: Vanderbilt Study Shows Gaps vs. Clinical Trials
Michael Albert, Co-Founder, Chief Medical Officer at Accomplish Health posted on X:
”Real-World GLP-1 Data: Vanderbilt Obesity Clinic Study (n=2,306)
Clinical trials showed 15–21% weight loss with semaglutide and tirzepatide. But how do patients actually fare in practice?
Key Findings:
Median treatment duration: 10.7 months (50% discontinued by 12 months)
Only 23% reached semaglutide 2.4 mg, 28% reached tirzepatide 15 mg
Weight loss for those who continued treatment:
• 6 months: –9.4%
• 12 months: –14.4%
13.6% had medication-related ER visits (mostly GI side effects)
Context:
This was not a typical setting—patients had multidisciplinary support and NO-COST medication access through employer insurance bundles.
Reality Check:
– With the right care model, real-world outcomes can approach RCTs
– Most patients never reach target doses
– Half stop treatment within a year
The gap between “can work” and “does work” remains large. Sustained success appears tied to comprehensive care models that most patients can’t easily access.”
Read the full study here.
Stay updated with Hemostasis Today.
-
Nov 29, 2025, 18:55Ahmad Thuaimer: Success Story – Advanced Interventional Care for DVT
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology
-
Nov 29, 2025, 16:42Vikas Dua: Heme Next 1.0 A Conference with a Difference
-
Nov 29, 2025, 16:41Hind Ali: Sources Of Error in Cell Counts
-
Nov 29, 2025, 16:40Maxime Dely: Even on a Break, You Can Give
-
Nov 29, 2025, 16:39Shrinidhi Nathany: HemeNext Brings Science, Technology, and Leadership Together